NVCR News and Press, NovoCure Limited From 05/10/19

Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD ) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Pr...

Start Time: 08:00 End Time: 08:40 Novocure Limited (NVCR) Q1 2019 Earnings Conference Call May 02, 2019, 08:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Wilco Groenhuysen - CFO Ely Benaim - CMO Ashley Cordova - SVP, Finance and IR C...

NovoCure ( NVCR )  Q1 results : Revenues: $73.3M (+40.7%). More news on: NovoCure Limited, Healthcare stocks news, Earnings news and commentary, Read more ...

The following slide deck was published by NovoCure Limited in conjunction with their 2019 Q1 earnings Read more ...

NovoCure (NASDAQ: NVCR ): Q1 GAAP EPS of -$0.13 beats by $0.02 . More news on: NovoCure Limited, Earnings news and commentary, Healthcare stocks news, Read more ...

Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018 Mesothelioma humanitarian device exemption application under FDA review Enrollment ongoing in four phase 3 pivotal trials, crea...

The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning The International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, is the official journa...

Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer Novocure (NASDAQ: NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highligh...

The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. The grants represent a joint effort between Novocure (NASDAQ: NVCR) and the AACR to promote and support i...

Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended Ma...